These results suggest that cRGDfK exerts an enhancing effect on A549 cell viability and TGF-β1-induced EMT as a targeting peptide that increases the drug efficacy of sunitinib in lung cancer cell death, the EMT process and invasion. The gene discussed is TGFB1; the disease is lung carcinoma.